All In Biotech

Drug Trial Radar · NCT04725994

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

An Open-Label, International, Multicenter, Phase 1b/2a Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX (Capecitabine and Oxaliplatin) or Irinotecan in Patients With Advanced Gastric Cancer

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

87

Actual

Start

Jun 28, 2021

Primary completion

Jul 31, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Idience Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.

Conditions

  • Gastric Cancer

Interventions

  • IDX-1197+XELOXDrug

    The dose levels will be escalated following a 3+3 dose escalation scheme.

  • IDX-1197+IrinotecanDrug

    The dose levels will be escalated following a 3+3 dose escalation scheme.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Time frame: through study completion (Up to 12 months)
  2. Dose Limiting Toxicities (DLTs)Time frame: during the first 21-day cycle for Group 1 and through first 2 cycles (14 days each) for Group 2

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • USC Norris Comp. Cancer Ctr Hospital

    Los Angeles, California

  • Hematology Oncology Clinic Baton Rouge / Sarah Cannon

    Baton Rouge, Louisiana

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Beijing Cancer Hospital

    Beijing, China

  • The Sixth Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, China

  • Shanghai East Hospital

    Shanghai, China

  • Dong-A University Hospital

    Busan, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital - Yonsei Cancer Center

    Seoul, South Korea

  • Jeonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.